|
Malignant Neoplasms
|
0.600 |
CausalMutation
|
group |
CGI |
|
|
|
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
A comparison of the Cancer and Steroid Hormone Study (CASH) model and a model which assumes a rare dominant susceptibility locus with low penetrance and no phenocopies stresses the difficulties in assessing linkage if the assumptions of the CASH model in terms of age at onset of breast cancer are not appropriate for the BRCA1 locus.
|
8460640 |
1993 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Markers from this map can be used to determine whether cancer is linked to BRCA1 in families, to evaluate whether tumors have lost heterozygosity at loci in the region, and to identify probes for characterizing chromosomal rearrangements from patients and from tumors.
|
8244378 |
1993 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Genetic recombination between IGFBP4 and BRCA1 places IGFBP4 centromeric to the cancer susceptibility gene and effectively excludes it as a candidate gene for BRCA1.
|
7507078 |
1993 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
It is noteworthy that allele losses involve larger chromosome fragments in malignant tumors than in benign lesions where BRCA-1 is not lost, suggesting a similar mechanism for genomic deletion in the tumorigenesis of the colon and of the breast.
|
8290255 |
1994 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
|
7907678 |
1994 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Approximately two-thirds of women unaffected by malignancy and alive at the time of observation were non-BRCA1 carriers.
|
7820489 |
1994 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
If the risk of cancer in these families is assumed to be restricted to the ovary, the best estimate of the proportion of families linked to BRCA1 is .78 (95% confidence interval .32-1.0).
|
7977348 |
1994 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
It is estimated that in 100% of these families, there is linkage to a cancer susceptibility gene on chromosome 17q, BRCA1.
|
7922985 |
1994 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
In addition, increased transcription of mammary Brca1 during pregnancy might contribute, in part, to the reduced cancer risk associated with exposure to pregnancy and lactation.
|
7590247 |
1995 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
A genetic recombinant in a breast-ovarian cancer family indicates a placement of BRCA1 telomeric to D17S776, and helps to define the region of assignment of the cancer susceptibility gene.
|
7759076 |
1995 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
These data are consistent with the hypothesis that BRCA1 mutations are involved in the etiology of hereditary ovarian carcinomas but occur rarely in sporadic tumors, and that the frequent allelic loss on chromosome 17q in this cancer type reflects the involvement of an additional tumor suppressor gene(s).
|
7606717 |
1995 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
To establish whether known risk factors modify susceptibility to cancer in these women, we have studied the reproductive histories of 333 North American women who were found by haplotype analysis to carry BRCA1 mutations.
|
8550241 |
1995 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The recent cloning of BRCA1 allows for the direct detection of mutations, but the feasibility of presymptomatic screening for cancer susceptibility is unknown.
|
7611277 |
1995 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
We describe a 43-year-old woman from a hereditary breast-ovarian cancer (HBOC) family which showed linkage to BRCA1 and who was at inordinately high risk for cancer but who was denied insurance coverage for prophylactic oophorectomy, despite strong recommendations by her gynecologist and a cancer geneticist-medical oncologist.
|
7705697 |
1995 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
The older age of onset in cases in which allele loss was seen only in the ovarian cancer suggests that the development of these cancers is not related to an inherited defect in BRCA1.
|
7892884 |
1995 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
We examined the application of our model to the above data using two assumptions, namely, that the proportion of cancers due to genetic susceptibility at the BRCA1 locus (1/200) and the frequency of the mutant allele (0.0033) estimated for Western populations are valid for Japanese women.
|
7652167 |
1995 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Differences in cancer risk profiles observed in these families with multiple ovarian cancer and in carriers of the gene BRCA1 suggest that hereditary ovarian cancer is genetically heterogeneous.
|
8620417 |
1995 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Mutations of the BRCA1 gene in human cancer.
|
8695765 |
1996 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Seventy-nine patients with ovarian cancer, 62 hospitalized women without cancer (controls), and 120 healthy women participating in a fragile X screening program (also controls), examined for the presence of germline BRCA1 185delAG mutation.
|
8946903 |
1996 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Validation of family history of breast cancer and identification of the BRCA1 and other syndromes using a population-based cancer registry.
|
8722746 |
1996 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The observed overrepresentation of specific mutations within a subgroup of the general population may eventually contribute to the development of inexpensive and routine tests for BRCA1 mutations, as well as to the elucidation of other contributory factors (e.g., diet, environment, and chemical exposures) that may play a key role in cancer initiation and development.
|
8651293 |
1996 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
A family history of pancreatic adenocarcinoma is not common in patients with this disease, but recent research has shown that pancreatic adenocarcinoma can be a feature of cancer susceptibility syndromes associated with germline mutations in p16, BRCA1, BRCA2, and APC.
|
8950667 |
1996 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Treatments that are aimed at increasing the apoptotic threshold by BRCA1 gene therapy may have the potential to prevent the progression of these malignancies.
|
8700535 |
1996 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Furthermore, the potential relationship of BRCA1 gene to ovarian tumors of borderline malignancy remains also unclear.
|
8632895 |
1996 |